BAGE5 Inhibitors
BAGE5 inhibitors are a class of chemical compounds that target the BAGE5 (B melanoma antigen family member 5) protein, which belongs to a larger group of proteins involved in various cellular processes, particularly those related to gene expression and intracellular signaling pathways. The BAGE5 protein is expressed in specific cell types and is believed to play a role in cellular differentiation, proliferation, and regulation of gene activity. BAGE5 inhibitors function by binding to the BAGE5 protein or its interacting partners, blocking its normal molecular interactions and thus interfering with its role in cellular processes. This disruption can have downstream effects on key functions such as protein synthesis, signal transduction, and other regulatory mechanisms within the cell.
BAGE5 inhibitors are small molecules designed with a high degree of specificity to interact with distinct regions of the BAGE5 protein. These inhibitors are typically optimized to form stable interactions with the target protein through a combination of non-covalent forces, including hydrogen bonds, van der Waals forces, and hydrophobic interactions. The structural diversity of BAGE5 inhibitors allows for variations in binding affinity, selectivity, and potency, making different inhibitors more or less effective depending on their chemical composition. Researchers in this field focus on refining these molecular properties to achieve the desired inhibitory effects in experimental settings. The ability of these inhibitors to selectively target BAGE5 enables a deeper understanding of the protein's role in cellular pathways, providing valuable insights into the biochemical networks in which BAGE5 is involved. Through this research, scientists can explore the broader functions of the BAGE5 protein and its impact on cellular regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that halts the cell cycle in G1 phase, leading to reduced tumor cell proliferation. As BAGE5 is implicated in cancer, inhibiting cell cycle progression may indirectly reduce the levels and influence of BAGE5 by halting the proliferation of cells expressing it. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor that interrupts the MAPK/ERK pathway, which is often upregulated in cancers. By doing so, it could indirectly lower the influence of BAGE5 by reducing the oncogenic signaling that may contribute to its expression. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
BRAF inhibitor that targets the MAPK/ERK signaling pathway, particularly in BRAF-mutated melanomas. As BAGE5 is a cancer/testis antigen, its expression in melanoma could be affected by the alteration of signaling pathways pivotal for tumor survival and proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that impedes cell growth and proliferation by interfering with the PI3K/AKT/mTOR pathway, potentially decreasing the functional activity of BAGE5 in cancer cells by promoting a less favorable environment for cell growth where BAGE5 might be upregulated. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
MEK inhibitor that can suppress the MAPK/ERK pathway, potentially leading to a decrease in the activity of BAGE5 by altering signaling pathways involved in cell proliferation where BAGE5 may play a role. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor that may indirectly influence BAGE5 activity by affecting DNA repair pathways and thereby potentially affecting the survival of cells that express BAGE5. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that can cause a buildup of proteins within the cell, leading to apoptosis. This could indirectly lead to the inhibition of BAGE5 activity by reducing the survival of cells where BAGE5 is expressed. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
EGFR inhibitor that blocks the EGFR signaling pathway, which may indirectly affect BAGE5 by reducing proliferative signals in cancer cells where BAGE5 is potentially implicated. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor that disrupts signaling involved in cell proliferation and survival. By inhibiting EGFR, it may indirectly inhibit BAGE5 by affecting cancer cell viability where BAGE5 is expressed. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted receptor tyrosine kinase inhibitor that could indirectly influence BAGE5 by targeting pathways critical for tumor cell survival and angiogenesis, potentially impacting the tumor cells expressing BAGE5. | ||||||